Evidence map›Paper›PMID 29108389›Full record

ArticleOncotarget2017

Hodgkin lymphoma in adolescent and young adults: insights from an adult tertiary single-center cohort of 349 patients.

Camille Bigenwald, Jacques-Emmanuel Galimard, Laurent Quero, Aurélie Cabannes-Hamy, Catherine Thieblemont, Nicolas Boissel, Pauline Brice

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Article
  3. Observational
  4. Late-effect awareness and follow-up of cancer in general practice.Scandinavian journal of primary health care · 2022
    Article
  5. NFATc1 is Suppressed in Tumor Microenvironment of Hodgkin Lymphoma.Asian Pacific journal of cancer prevention : APJCP · 2021
    Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Camille BigenwaldDepartment of Onco-Hematology, Hôpital Saint Louis, Assistance Publique des Hôpitaux de Paris (AP-HP), Université Paris, Paris, France.
Jacques-Emmanuel GalimardDepartment of Biostatistics and Medical Information (ECSTRA Team), Center of Research in Epidemiology and Statistics Sorbonne, Inserm UMR 1153, Université Paris Diderot, Paris, France.
Laurent QueroDepartment of Radiation Oncology, Hôpital Saint Louis, AP-HP, Université Paris, Paris, France.
Aurélie Cabannes-HamyHematology Adolescents and Young Adults Unit, Hôpital Saint-Louis, AP-HP, Université Paris, Paris, France.
Catherine ThieblemontDepartment of Onco-Hematology, Hôpital Saint Louis, Assistance Publique des Hôpitaux de Paris (AP-HP), Université Paris, Paris, France.
Nicolas BoisselHematology Adolescents and Young Adults Unit, Hôpital Saint-Louis, AP-HP, Université Paris, Paris, France.
Pauline BriceDepartment of Onco-Hematology, Hôpital Saint Louis, Assistance Publique des Hôpitaux de Paris (AP-HP), Université Paris, Paris, France.
Hôpital Saint-Louis · FRAssistance Publique – Hôpitaux de Paris · FRCentre de Recherche Épidémiologie et Statistique

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdolescent and young adults (AYA) represent one third of patients affected by Hodgkin lymphoma (HL). These patients are frequently treated either with pediatric or adult protocol depending on their physician background. This population has been understudied so far, in terms of HL characteristics and treatment-associated outcomes.

aimWe aimed to extensively describe HL features in the AYA population including HL characteristics, progression-free (PFS) and overall survival (OS).

methodsFrom 1979 to 2013, consecutive patients with HL aged between 15 to 25 years and followed at Saint-Louis Hospital were prospectively enrolled. Survivals were estimated using the Kaplan-Meier method.

results349 patients were included and studied, with a median follow-up of 7 years. The majority of patients were treated with adult protocols (mainly ABVD and BEACOPP). They presented adverse clinical characteristics with a high proportion of stage III and IV according to Ann Arbor classification (45 %), a high rate of B symptoms (46 %) and extra-nodal involvement (36 %). Despite these pejorative clinical features, the prognosis remains good with a 10-year PFS and OS estimated at 81.0 % (95%CI [76.7-85.5]) and 90.7% (95%CI [87.2-94.4]), respectively. In multivariate analysis, stages III and IV according to Ann Arbor classification, mixed cellularity histology, elevated neutrophils and LDH above range were independently associated with a worse PFS. We identified a subgroup of 11 primary refractory patients with a particularly poor prognosis. The toxicity rate was low (7.4 %).

conclusionDespite their baseline pejorative features, AYA with HL have a good prognosis. Progresses are still needed in order to reduce toxicities. Primary refractory patients with a particularly poor prognosis should be detected early in order to quickly introduce new targeted therapies.

Indexed as

adolescentsHodgkinyoung adults

Identifiers

PMID29108389
PMCPMC5668122
OpenAlexW2751045646

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.